Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04060342
Title GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

pancreatic adenocarcinoma

prostate cancer

gastric adenocarcinoma

stomach cancer

colorectal cancer

gastroesophageal adenocarcinoma

pancreatic cancer

esophagus adenocarcinoma

triple-receptor negative breast cancer

esophagus squamous cell carcinoma

colorectal adenocarcinoma

gastroesophageal junction adenocarcinoma



GB1275 + Pembrolizumab

GB1275 + Gemcitabine + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) Recruiting Aurora Colorado 80045 United States Details
Washington University School of Medicine - Siteman Cancer Center Recruiting Saint Louis Missouri 63110 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Duke University Medical Center Recruiting Durham North Carolina 27710 United States Details
The Sarah Cannon Research Institute/Tennessee Oncology Recruiting Nashville Tennessee 37203 United States Details
South Texas Accelerated Research Therapeutics, LLC Recruiting San Antonio Texas 78229 United States Details
The Royals Marsden NHS Foundation Trust Recruiting Sutton Surrey SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from for the field